Coronary Heart Disease News and Research

RSS

Naturalhealthylife.co.uk celebrates National Garlic Day

Naturalhealthylife.co.uk, the official UK site for herbal supplements made by Klosterfrau, are celebrating National Garlic Day on Monday 19th April. Klosterfrau is a leading manufacturer of herbal healthcare products.

29 Mar 2010

Ford Motor donates $255,000 to fund completion of Oakwood Healthcare System's research study

Ford Motor Company announced today it is donating an additional $255,000 to fund the completion of a pioneering multi-year Oakwood Healthcare System research study into the prevention of heart disease – a leading cause of death among American women.

27 Mar 2010

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Celera Corporation today announced the publication of data reporting that elderly (over age 70) carriers of the KIF6 gene variant with prior vascular disease received significant benefit from pravastatin (Pravachol®) therapy. Previous research has shown that a variant of the KIF6 gene, a member of the molecular motor protein kinesin family, is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) events in the placebo arms of the clinical trials, and that this increased risk is virtually eliminated with statin therapy.

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

Study: Replacing dietary saturated fats with polyunsaturated fatty acids reduces coronary heart disease

A study in this week's PLoS Medicine shows that the replacement of dietary saturated fatty acids with polyunsaturated fatty acids reduces coronary heart disease events, bringing much needed scientific evidence to an issue debated by experts and clinical guidelines.

23 Mar 2010

AstraZeneca's CRESTOR: Health Canada approves new indication

AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.

17 Mar 2010

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

17 Mar 2010

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating to New Targets (TNT) trial that were designed and completed following the completion of TNT, were presented today at the 59th Annual Scientific Session of the American College of Cardiology (ACC) in Atlanta, Ga.

16 Mar 2010

Tips for reducing LDL cholesterol

Cardiovascular disease is the No.1 killer in North America. And high cholesterol is one of the primary risk factors of coronary heart disease and stroke. According to the Heart and Stroke Foundation, almost 40% of Canadian adults are classified as having high blood cholesterol levels.

16 Mar 2010

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

16 Mar 2010

High ABI may indicate risk for future heart attacks

The prevalence of abnormal ankle-brachial index (ABI) test results among individuals tested for peripheral arterial disease (PAD)—and who are not considered at high risk of a coronary heart event by Framingham-based risk factors—is high and provides another way to identify those who may be at risk for future heart attacks, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

Researchers develop Intermountain Risk Score tool to assess patients' health

Researchers from the Heart Institute at Intermountain Medical Center in Murray, Utah, have devised a better way to determine an individual's risk for problems, such as heart attack and heart failure, according to a new study.

15 Mar 2010

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

15 Mar 2010

A new way to control blood pressure

The control of blood pressure is central to people's wellbeing. One in three Australians suffer from high blood pressure (hypertension), a condition which can lead to coronary heart disease, heart failure, stroke and kidney failure.

11 Mar 2010

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

BioInvent International AB and Human Genome Sciences, Inc. today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

African-Americans and Hispanics are at higher risk for developing Alzheimer's and dementias

According to the Alzheimer's Association's® 2010 Alzheimer's Disease Facts and Figures, African-Americans are about two times more likely and Hispanics are about one and one-half times more likely than their white counterparts to have Alzheimer's and other dementias.

10 Mar 2010

Study reveals feasibility of physician-pharmacist collaborative care plan for managing dyslipidemia

The use of a physician-pharmacist collaborative care plan to manage lipid control in patients with high cholesterol does not have significant clinical impact, found an article in CMAJ.

9 Mar 2010

Evaluating asymptomatic diabetics for CHD: Speckle Tracking by Echo ultrasound substudy sponsored

Cardiovascular death is the most common cause of mortality among Type 2 diabetics and claims the lives of millions each year, with many diabetics experiencing their first “symptom” as a heart attack or sudden death. Understanding that diabetics are at high risk for Coronary Heart Disease (CHD) and that many with the disease are asymptomatic, Toshiba America Medical Systems, Inc., has sponsored Speckle Tracking by Echo, a faCTor64 substudy using Toshiba’s Wall Motion Tracking ultrasound technology.

8 Mar 2010

Adams Food Ingredients launches new additives to enhance nutritional values of foods

Adams Food Ingredients Limited, the functional ingredients division of The Irish Dairy Board (based in Leek), has launched a range of additives to help food manufacturers enhance the health and nutritional values of their products.

4 Mar 2010

Coronary Heart Disease News and Research

Naturalhealthylife.co.uk celebrates National Garlic Day

Ford Motor donates $255,000 to fund completion of Oakwood Healthcare System's research study

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Study: Replacing dietary saturated fats with polyunsaturated fatty acids reduces coronary heart disease

AstraZeneca's CRESTOR: Health Canada approves new indication

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Tips for reducing LDL cholesterol

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

High ABI may indicate risk for future heart attacks

Researchers develop Intermountain Risk Score tool to assess patients' health

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

A new way to control blood pressure

BioInvent International, HGS announce collaboration to develop therapeutic monoclonal antibodies

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

African-Americans and Hispanics are at higher risk for developing Alzheimer's and dementias

Study reveals feasibility of physician-pharmacist collaborative care plan for managing dyslipidemia

Evaluating asymptomatic diabetics for CHD: Speckle Tracking by Echo ultrasound substudy sponsored

Adams Food Ingredients launches new additives to enhance nutritional values of foods

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News